Loading...
Market
Will TECELRA® be covered by major insurance providers by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official statements from major insurance providers and Adaptimmune
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA® for Advanced Synovial Sarcoma
Aug 1, 2024, 06:03 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking it as the first approved engineered cell therapy for a solid tumor. This milestone approval extends the power of immunotherapies into difficult-to-reach sarcomas, specifically targeting advanced synovial sarcoma, a rare cancer that arises in the body's soft tissues. Adaptimmune's TECELRA® is also noted as a significant development in TCR gene therapy.
View original story
Similar markets
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Yes • 50%
No • 50%
Less than 20 • 33%
20-40 • 33%
More than 40 • 33%
Yes • 50%
No • 50%
All major insurers • 25%
Most major insurers • 25%
Some major insurers • 25%
Few or none • 25%
Yes • 50%
No • 50%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%